Brief: Algernon Provides Update On Phase 2 Human Testing Of Ifenprodil For COVID-19
02/04/2020 13:55
April 2 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PROVIDES UPDATE ON PHASE 2 HUMAN TESTING OF
IFENPRODIL
FOR COVID-19
* ALGERNON PHARMACEUTICALS - PLANNED PHYSICIAN INITIATED
PHASE 2
STUDY OF NP-120 FOR COVID-19 INFECTED PATIENTS IN SOUTH KOREA
HAS BEEN FINALIZED
Source text for Eikon: ID:nGNXd93rZ
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement